Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Financing Activities (2019 - 2021)

Historic Cash from Financing Activities for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q3 2021 value amounting to $64000.0.

  • Black Diamond Therapeutics' Cash from Financing Activities fell 7629.63% to $64000.0 in Q3 2021 from the same period last year, while for Dec 2021 it was $729000.0, marking a year-over-year decrease of 9966.08%. This contributed to the annual value of $25.5 million for FY2024, which is 6448.45% down from last year.
  • According to the latest figures from Q3 2021, Black Diamond Therapeutics' Cash from Financing Activities is $64000.0, which was down 7629.63% from $184000.0 recorded in Q2 2021.
  • Black Diamond Therapeutics' 5-year Cash from Financing Activities high stood at $213.8 million for Q1 2020, and its period low was -$70000.0 during Q2 2019.
  • Moreover, its 3-year median value for Cash from Financing Activities was $481000.0 (2021), whereas its average is $38.2 million.
  • Examining YoY changes over the last 5 years, Black Diamond Therapeutics' Cash from Financing Activities showed a top increase of 7629.63% in 2021 and a maximum decrease of 9977.51% in 2021.
  • Quarter analysis of 3 years shows Black Diamond Therapeutics' Cash from Financing Activities stood at $83.5 million in 2019, then crashed by 99.01% to $830000.0 in 2020, then tumbled by 92.29% to $64000.0 in 2021.
  • Its last three reported values are $64000.0 in Q3 2021, $184000.0 for Q2 2021, and $481000.0 during Q1 2021.